AN
Anebulo Pharmaceuticals, Inc.
ANEB · OTC
$0.39 +8.76% (+$0.03)
1M +19.53%
Market Cap $15.9M
P/E Ratio -
Div. Yield -
ROE 74.58%
Bulios Fair Price
$0.54
38.5% upside
Current Price
$0.39
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANEB is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
87 /100
Cheap P/B 2.00x
P/FFO N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 8.20%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 74.58%
ROA 84.68%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 16.71x
Int. coverage -25.82x
Debt/Equity 0.00x
Stability
34 /100
Moderate EPS volatility 51.61%
Profitable years 0
Beta -1.82x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANEB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Anthony Cunningham
Employees
3
Headquarters
Lakeway
Upcoming events
23 SEP
Earnings
Upcoming earnings report